Finding biological types of adult-onset diabetes to guide prevention
Heterogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subphenotypes and Evaluate Targeted Prevention
This project uses detailed blood tests and physiologic measurements to find different biological types of adult-onset diabetes and help guide prevention for adults with prediabetes or early type 2 diabetes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11249606 on NIH RePORTER |
What this research studies
You would have detailed blood samples, metabolic studies, and other clinical measurements taken while researchers collect genetic, protein, and metabolite data (multi-omics). Those data are combined with gold-standard physiologic tests to classify people into subtypes based on problems such as insulin resistance, beta-cell dysfunction, reduced incretin effect, or liver insulin resistance. The team will link these subtypes to how complications develop and to responses to targeted prevention approaches. The overall aim is to match prevention and early treatment to the biology driving your glucose problems instead of using the same approach for everyone.
Who could benefit from this research
Good fit: Adults aged 21 and older with prediabetes or early-stage type 2 diabetes are the ideal participants for this project.
Not a fit: People without prediabetes or diabetes, children, and those with long-standing advanced diabetes are unlikely to benefit directly from this work.
Why it matters
Potential benefit: If successful, this work could let doctors choose prevention and early treatments that better match each person's biology, reducing complications and improving outcomes.
How similar studies have performed: Prior research has suggested that diabetes can be split into biological subtypes, but combining multi-omics with gold-standard physiologic testing for targeted prevention is relatively new.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Mclaughlin, Tracey — Stanford University
- Study coordinator: Mclaughlin, Tracey
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.